All In Biotech

Drug Trial Radar · NCT05999474

Combined Fractional CO2 Laser With Topical Tioconazole Versus Q-switched Nd:YAG Laser in the Treatment of Onychomycosis; a Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Aug 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

30

Planned (sponsor's estimate)

Start

Sep 1, 2022

Primary completion

Sep 1, 2023

Study completion Oct 1, 2023

Sponsor

Lead sponsor
Cairo UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Our aim is to assess the clinical efficacy and the safety of fractional CO2 laser combined with topical tioconazole versus Q-switched Nd:YAG laser in the treatment of OM.

Conditions

  • Onychomycosis of Fingernail

Interventions

  • Topical tioconazoleDrug

    Laser

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. treatment of onychomycosisTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kasr Alainy Faculty of Medicine

    Cairo, Egypt · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.